Short answer
KORU Medical Systems, Inc. (KRMD) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Standard 8-K liability disclaimer; no earnings figures or operating results disclosed in the provided text.
KORU Medical Systems, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Standard 8-K liability disclaimer; no earnings figures or operating results disclosed in the provided text
- Investor-relevant results, if any, are likely contained in an accompanying exhibit or separate earnings release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $12.0M, up 18.2%, led by international core growth of 59.1% and domestic core growth of 12.4%
- Gross margin improved to 65.1% from 63.5%, supporting gross profit growth of 21.2% to $7.8M
- Net income reached $0.25M versus a $0.21M loss; adjusted EBITDA rose to $0.86M from $0.34M
- 2026 guidance narrowed to $47.5M-$48.5M revenue, 62%-64% gross margin, positive adjusted EBITDA, and year-end cash above $7.5M
- Phesgo® U.S. 510(k) withdrawal shifts oncology strategy toward higher-volume molecules; technology acquisition cost reduced expected year-end cash availability
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other KORU Medical Systems, Inc. 8-K filings
Get the next KRMD 8-K as it lands
Follow KRMD for push alerts, or ask the research agent what this filing means.